Relapsed or Refractory Multiple Myeloma

• A study to evaluate the efficacy and safety of belantamab mafodotin in combination with standard of care in participants aged 18 years and o … Pending
  2025-523117-28-00 4
• A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending
  2025-523285-25-00 5
• A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-522007-18-00 5 2026-05-27
• Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple my … Recruiting
  2023-506993-11-00 1 2023-11-23
• A Phase 1b/2 Study of BGB-11417 as Monotherapy and in Various Combinations with Dexamethasone plus Carfilzomib, Dexamethasone plus Daratumum … Recruiting
  2023-507751-30-00 9 2024-05-27
• A First-in-Human Dose Escalation Study of JNJ-79635322, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated A … Recruiting
  2023-503679-12-00 1 2022-11-21
• Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma Recruiting
  2024-511454-45-00 7 2020-11-09
• A study to evaluate the dose optimization measures and safety of Etentamig (ABBV-383) in subjects with Relapsed or Refractory Multiple Myelo … Recruitment ended
  2023-504674-38-00 3 2023-07-31
• A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin … Recruitment ended
  2023-503467-41-00 5 2022-10-12
• A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants wit … Recruitment ended
  2022-502681-24-00 3 2022-06-22
• A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function Ended
  2023-509915-10-00 3 2021-07-27
• A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple My … Ended
  2023-504571-25-00 3 2020-10-20

Showing 1–12 of 12 trials